Three dimensional colorimetric assay assemblies

ABSTRACT

A direct assay is described using novel three-dimensional polymeric assemblies which change from a blue to red color when exposed to an analyte, in one case a flu virus. The assemblies are typically in the form of liposomes which can be maintained in a suspension, and show great intensity in their color changes. Their method of production is also described.

This invention was made with Government support under Contract NoDE-AC03-76SF00098 between the U.S. Department of Energy and theUniversity of California for the operation of Lawrence BerkeleyLaboratory. The Government has certain rights in this invention.

This is a continuation of application Ser. No. 08/389,475 filed on Feb.13, 1995,now abandoned, which is a continuation in part of prior-filedU.S. patent application Nos. 08/289,384 filed Aug. 11th, 1994, which isa continuation in part of 08/328,237 filed Oct. 24th, 1994, nowabandoned.

BACKGROUND OF THE INVENTION

The present invention relates to a method for direct detection ofanalytes using color changes in three-dimensional polymeric assemblieswhich occur in response to selective binding of analytes to theirsurface.

Analytical Chemistry

Analytical chemistry techniques have been used for many years todetermine such medical parameters as hematocrit levels. While useful intheir own right, analytical chemistry methods are of limited or nopractical applicability to many biological parameters in whichassessment would be valuable. Unless expensive and cumbersome gaschromatography methods are used, large quantities of analytes aregenerally required to accomplish such methods. Often, quantitativeresults are limited or not available. However, such techniques have beenused for such basic chemical tests as creatinine assays.

Microbiological and Pathology Methods

Another approach to medical-biological systems analysis has been directmicroscopic observation using various cell-staining and classicpathology techniques. Augmenting these capabilities have been welldeveloped microbiological techniques, such as culturing, colonycharacterization, and observation of metabolic and nutrient limitations.Most of medical science has been developed using this basic arsenal ofanalytic techniques. While culturing and direct tissue observationtechniques have served as the bulwark of medical detection processes formany years, they have considerable limitations.

Pathological analysis of patient tissues to determine the development ofa disease state and the identification of the causative pathogengenerally requires an invasive procedure. On the other hand, culturingthe pathogen from various body fluid or other samples is time consumingand expensive.

Immunoassays

A breakthrough in medicine occurred with the development of immunoassaytechniques. In these methods, an antibody is developed which willspecifically bind to a target of interest. While costly in both theirdevelopment and production, antibodies from animals allowed a veryaccurate analysis of a number of analytes which had previously beenvirtually unassessable in both research and particularly clinicalsituations.

An important technical advancement in immunoassay was the development ofmonoclonal antibodies. Instead of subjecting an animal to an analyte andharvesting its whole range of antibodies, in this techniques a singlespleen cell of a sensitized animal is rendered immortal and multipliedmany times. The resulting cell line is then cultured to produce a veryspecific and pure antibody product.

Because the antibody itself is a small molecule, it must be labeled insome way so that the binding event can be detected. This can be donewith a dye, fluorescent, radioactive or other label. Conversely, ifbinding inhibition occurs between a known amount of introduced, labeledanalyte and the material to be analyzed, the diminution of the signalwill indicate the presence of test analyte. If the agglutination of theantibody particles is of sufficient volume and density, the formation ofa precipitant can also serve to signal the presence of an analyte.

In recent years, the research and medical communities have come to relyheavily on immunoassay techniques to detect and quantify biologicalmaterials. While successful in many respects, the indirect nature ofimmunoassay methods as well as their dependence on antibody materials,results in a variety of complications, problems, and assay limitations.Briefly, the development and production of antibodies remains expensive,and these molecules are sensitive to environmental changes. Also, onlythose materials to which antibodies can be produce can be detected bythese systems.

Langmuir-Blodgett Film Assays

The techniques of molecular self-assembly, such as that described bySwalen et al., (Langmuir, Vol. 3, page 932, 1987) as well asLangmuir-Blodgett (LB) deposition (Roberts, Ed. Lancmuir-Blodaett Films,Wiley, N.Y., 1966) have been used for coating surfaces with awell-defined, quasi two-dimensional array of molecules. The initial usefor this new advancement was for materials science applications such aswetting (Whitesides, et al., Langmuir, Vol. 6, p. 87, 1990) and friction(Novotny et al., Langmuir Vol. 5, p. 485, 1989).

These bilayer films are also used as immobilizing supports for analyticreactions. Bio-sensors based on LB films can detect molecules ofdiagnostic significance such as glucose (Okahata, et al., Thin SolidFilms, Vol. 180, p. 65, 1989) and urea (Arisawa, et al., Thin SolidFilms, Vol. 210, p. 443, 1992). In these cases, classic analyticalchemistry systems are immobilized on the films in order to improve thereadout of the test results and otherwise simplify and improve thedetection capabilities of the test procedure.

The detection of receptor-ligand interaction is generally accomplishedby indirect assays such as the enzyme-linked immunosorbent andradio-labeled ligand assay. Although biotechnological functionalizedfilms have led to elegant examples of molecular recognition at aninterface, the problem of transducing the molecule recognition eventinto a measurable signal has remained a difficulty until the advent ofthe subject invention.

In the case of biosensor devices, detection is generally carried out bycoupling the LB films to a secondary device such as an optical fiber(Beswick, Journal Colloid Interface Science, Vol. 124, p. 146, 1988),quartz oscillator (Furuki et al., Thin Solid Films, Vol. 210, p. 471,1992), or electrode surfaces (Miyasaka, et al., Chemical Letters, p.627,1990).

Some of the analytes bound films provide for fluorescent label, wherethe fluorescence or its quenched state indicate the occurrence of abinding event (Beswick, Journal Colloid Interface Science, Vol. 124, p.146, 1988). In some cases, these detection materials have been embeddedin the surface of the supporting bi-lipid layer (Tieke, AdvancedMaterials, Vol. 3, p. 532, 1991).

Polydiacetylene films are known to change color from blue to red with anincrease in temperature or changes in pH due to conformational changesin the conjugated backbone (Mino, et al., Langmuir, Vol. 8, p. 594,1992; Chance, et al., Journal of Chemistry and Physics, Vol. 71, p. 206,1979; Shibutag, Thin Solid Films, Vol. 179, p. 433, 1989; Kaneko, etal., Thin Solid Films, Vol. 210, p. 548, 1992).

Functionalized Liposomes

Unpolymerized liposomes expressing sialic acid residues have beenextensively used as model systems to study the interaction betweeninfluenza virus and cell surfaces (Ott, et al., European Journal ofPharmacological Science, Vol. 6, p 333, 1994). These liposomes aretypically made of such lipid materials as cholesterol and eggphosphatidylcholine (Kingery-Wood, et al, Journal of the AmericanChemical Society, Vol. 114, p 7303, 1992).

In a publication which serves the basis for a U.S. patent applicationfrom which the subject application depends, is described a therapeuticfictionalized liposome which is produced through polymerization. Thestandard in the field is to progress with the polymerization procedureuntil the materials are fully red, indicating that the polymerization iscomplete. This was the procedure used in the above cited publication.

While it has been a goal of the research community to exploit thischaracteristic in the detection of binding events, researchers have yetto develop a method using this phenomenon in practical applications.

GENERAL DESCRIPTION OF THE INVENTION

The present invention allows direct detection of small molecules,pathogens, bacteria, membrane receptors and drugs, by the observation ofcolor changes which occur when these analytes bind to the inventivethree-dimensional polymeric assemblies. This technological advancementrepresents a dramatic improvement in results over the inventors 2-Dprior monolayer film work, in that the color intensity is dramaticallyimproved. Additionally, the present work enjoys the many advantageswhich accrue when a test system can be suspended in fluid or bound tovarious supports.

It is an object of the present invention to assay the presence ofbiomolecules by directly detecting the binding event when the analytesspecifically binds to three-dimensional polymeric assemblies.

It is a further object of the present invention to provide for thedirect detection of viruses, bacteria, parasites, and other pathogens,and drugs, hormones, cell wall fragments, membrane fragments, membranereceptors, enzymes, radioactive materials, hormones, blood components,disease indicators, cell components, antibodies, lectins, organicsolvents, pollutants, genetic material, and other biologically relevantmaterials using the inventive assay system. Detected viruses include,but are not limited to, influenza, cold, rubella, chicken pox, hepatitisA, hepatitis B, herpes simplex, polio, small pox, plague, humanimmuno-deficiency virus, rabies, Epstein Barr, reovirus, rhinovirus, andmutations, strains, and ligand recognizable parts thereof. Detectedbacteria include, but are not limited to, E. coli, tuberculosis,salmonella, streptococcus, and mutations, strains and degraded partsthereof. Detected parasites and other pathogens include, but are notlimited to, malaria, sleeping sickness, river blindness, andtoxoplasmosis.

It is another object of the present invention to provide for thedevelopment and improvement of drugs by observing competitive inhibitionof natural binding events between all surfaces or binding cites andtheir natural bioactive ligand.

It is yet another object of the invention to provide means of testinglibraries of materials, as the binding can be observed and the relevantliposome with its relevant ligand segregated from the others bysegregating out a particular polymeric structure.

The inventive assemblies can be bound to solid supports including, butnot limited to sephadex, silica gel, sepharose, polyacrynitriles,filters, gold, silicon chips, and silica gel.

The present inventive assay means and method provide for the directcalorimetric detection of a receptor-ligand interaction using a novelthree-dimensional polymeric assemblies system. Using the inventivemethod of producing these original assemblies, a ligand or itsderivative is rendered polymeric by polymeric linking of the ligandsthough a linking arm, or though direct incorporation during thepolymerization process. Some of these aspects of the present inventionare described in the inventor's recently published communication,incorporated by reference herein, (Reichert et al, J. Am Chem. Soc.,Vol. 117, p 829, 1995). Ligands include, but are not limited to,peptides, carbohydrates, nucleic acids, biotin, drugs, chromophores,antigens, chelating compounds, molecular recognition complexes, ionicgroups, polymerizable groups, linker groups, electron donors, electronacceptor groups, hydrophobic groups, hydrophilic groups, receptorbinding groups, antibodies, epidermal growth factor, acetylcholinereceptor, complement receptor, beta-adrenergic receptor, ICAM- 1, poliovirus receptor, trisaccharide, tetrasaccharide, ganglioside G_(Ml) andganglioside G_(T1b), sialic acid, CD4, sCD4, CD26, vasoactive intestinalpeptide, peptide T, and combinations thereof.

The presence of an analyte which binds to the incorporated ligands canbe detected by observing changes in the spectral characteristics of thepolymeric assemblies. The polymer-ligand assembly thus encompasses amolecular recognition site and a detection sites, all within a singlemolecular assembly.

In one embodiment of the invention, chromatic polydiacetylenic liposomesare produced, and placed in a liquid. Materials other thanpolydiacetylenes are contemplated, including, but not limited to,acetylenes, alkenes, thiophenes, polythiophenes, imides, acrylamides,methacrylates, vinylether, malic anhydride, urethanes, allylamines,siloxanes anilines, pyrroles, vinylpyridinium, and combinations thereof.The headgroups of such materials can include, but are not limited tocarboxylic acid, hydroxyl groups, amine groups, amino acid derivatives,and hydrophobic groups. The test sample is added. The color change whichoccurs indicates the presence of the analyte, and the intensity of thecolor allows a quantification of the analyte's concentration.

In the liposome embodiment of the present invention, the inventors haveprepared synthetic, polymerizable liposomes that resemble theorganization and functionalization of cell membranes and have employedthem as simple calorimetric sensors. The liposomes were designed tospecifically bind to influenza virus particles and, in addition, reportthe binding event by undergoing a visible color change. In effect, thesemolecular assemblies mimic cell surface molecular recognition as well assignal transduction.

In order to impart both molecular recognition and detection functions tothe liposomes, the inventors combined a known ligand--receptorinteraction with the unique optical properties of polydiacetylenes. Theconjugated backbone of alternating double and triple bonds gives rise tointense absorptions in the visible spectrum. In single crystals orLangmuir-Blodgett films, these materials are known to undergo blue tored color transitions due to a variety of environmental perturbationsincluding heat, mechanical stress, pH, and solvent.

In one embodiment of the subject invention, the inventors havedemonstrated that specific binding of influenza virus to functionalizedpolydiacetylene liposomes produces an analogous color transition. Inearlier work, the inventors showed that similar effects can be obtainedwith functionalized 2-D polydiacetylene Langmuir-Blodgett films.(Charych, et al., Science Vol. 261, p 585, 1993).

Influenza virus particles are enveloped by a lipid bilayer to which thehemagglutinin (HA) lectin is anchored. HA binds to terminal alphaglycosides of sialic acid on cell-surface glyco-proteins andglycolipids, initiating cell infection by the virus. As described in theprior art section of the subject application, liposomes expressingsialic acid residues have been extensively used as model systems tostudy the interaction between influenza virus and cell surfaces. Thepolymerized liposomes of the subject invention, however, are composed ofmolecules that allow direct visualization of this specific interaction.

Advantages of the Invention

Analytical Chemistry Techniques

Analytical chemistry techniques are the only assay system prior to theadvent of the subject invention that allows direct detection.Unfortunately, analytical chemistry have limited applicability to manybiological system's assay needs. Unless expensive and cumbersome gaschromatography methods are used, large quantities of analyte arerequired. Often, quantitative results from such methods are limited ornot available. However, such techniques have been used for such tests ashematocrit analysis, and creatinine assays.

Analytical chemistry methods are virtually unavailable for mostbiological molecules due to the destruction of the analytescharacteristics during preparation and analysis steps, and the typicallysmall amount of the analyte present in the test sample. For thesereasons, the advent of immunoassay techniques were revolutionary in thebiological sciences.

Immunoassays

Many small biological molecules are notoriously difficult to assay in adirect manner due to the severe limitation of environmental ranges whichthey can tolerate without losing their specific characteristics. Forthese among other reasons, immunoassays have been heavily relied upon toassay these classes of materials. While successful in many respects, theindirect nature of immunoassay methods results in a variety ofinterferences, complications, problems, and assay limitations.

The requirement that an antibody be developed and produced for eachpossible target limits the efficacy of immunoassay methods in suchapplications as designer drug development and screening. Ironically,while allowing testing within a portion of biological environmentalranges, the large glycoproteinaceous antibody are often highly sensitiveto degradation outside of a small testing parameter environmental range.Thus, the susceptibilities of antibodies too rigorously limit theenvironmental testing range available in these assay systems.

A subtle disadvantage to immunoassay systems occurs in rapidly evolvingpathogens such as the influenza virus. In such organisms, especially inthe case of viruses, the external coat which is available for immunereactions has become constantly shifting in its antibody recognitionelements. Thus, despite a full blown immunity response to an influenzastrain, within months an individual can again develop flu, but from apathogen with an external coat so modified that it is immunologicallyunrecognizable by the victims memory cells. This is the reasonindividuals can develop flu year after year.

Unique Qualities of the Present Invention

The present invention enjoys the unique advantage over bothimmunumoassay and analytical chemistry techniques of directly detectingbiological analytes. In contrast to assays requiring binding toimmunoglobulins, in one embodiment of the present invention, the hostattachment site on the pathogen is exploited for recognition function.This site, generally in an immunologically inaccessible valley on thepathogen surface, is highly genetically conserved over time. The minimalvariability of this site is necessary for the pathogen to maintain itsinfectivity. As a result, a single assay system of the present inventionwill provide effective assays for a panoply of influenza strains, manyof which may be very newly evolved.

There are many advantages to the genetically conserved host recognitionsite being targeted by the embodiment of the present invention. Adetermination of a patient's exposure to the flu will be definitive, andnot limited to a particular strain. This advantage of the presentinvention also avoids the need for a large number of immunologicaltests, as the clinician can rely on a single assay. Additionally, evennewly evolved, uncharacterized flu strains can be identified, furtheravoiding false negative tests.

An analogous limitation of immunoassays occurs in well establishedpathogens such as malaria parasites. In these organisms, phases of thelife cycle which would allow for an immune response have over time beenso limited as to avoid the immune response, or have been made to occurwithin host cells so as to avoid an antibody reaction.

The present invention exploits the genetically conservative host bindingsite to identify the pathogen. Even in comparatively large parasites,the host binding site tends to be held constant over time throughout thegenerations of pathogens. Additionally, parasites are usually present inthe body in a large number of diverse life stages. In well establishedparasites, the immune accessible sites often vary considerably fromstage to stage, the advantage being that the host organism is unable tomount a immunological response with sufficient rapidity to avoid theentrenchment of the parasite.

General Advantages of the Invention

The subject invention represents a dramatic advancement over both priorart direct chemical and immunoassay systems, achieving advantages which,prior to the present invention, where available exclusively in only oneor the other of these analytic art methods. Much as the advent ofimmunoassay techniques revolutionized medical and research analyticalcapacities, the subject invention represents a critical advance in theanalytical arts.

The present invention allows the advantages of both immunoassay andchemical analysis in a single system. The present invention enjoys thedirect assay advantages of analytical chemistry methods, with many ofthe advantages inherent in such systems. The inventive assay techniquealso has a substantial environmental range of testing beyond that ofimmunoassays. This allows the accommodation of various analytes in theirmost advantageous environmental parameters. Additionally, the presentinvention allows rigorous, direct analysis to occur even in very narrowenvironmental ranges, previously unavailable with analytical chemistrytechniques. The speed and simplicity of the color change indicator ofthe subject invention are its hallmark advantages.

Target Materials

One of the unique advantages of the subject invention is the wide rangeof target materials, binding events, and biochemical reactions amenableto analysis using the inventive techniques. Many of these materialspreviously could not be detected using a straightforward, practicalassay. The present invention allows many advantages of immunoassaysystems, without the complications of immunoglobulin generation orindirect analysis.

In general, the present invention requires no pre-analysis purificationstep. This feature of the subject invention is due to the highspecificity of the ligands incorporated into the detecting polymericassembly. Additionally, the inventive direct assay system avoids theexpense, complications, and increased inaccuracies inherent in theindirect systems currently available.

Sensitive Analytes-Gentle Testing Conditions

The inventive polymeric assemblies can employ ligands and analytes whichare stable or enjoy appropriate binding characteristics a limited invitro or environmental range of conditions. Within in vitro rangeconditions, the present invention is useful in that stringentlimitations even within this narrow range of conditions can be met. Thisallows, for instance, three dimensional conformations of sensitivebiochemicals and biomolecules to be maintained throughout the testingprocedure.

The present invention functions well even in carefully limitedconditions. Thus, conditions such as pH, saline, and temperature can becarefully controlled by feedback controls, titration and othertechniques without interfering with the accuracy or sensitivity of theanalysis.

Because of this wide experimental range advantage of the presentinvention, intact cells or sensitive subcellular inclusions can beassayed without disturbing their structural integrity. The color changewhen the inventive assemblies bind to a surface will pinpoint thelocation of an analyte, such as in a tissue sample.

Subtle cellular development stages can be monitored by the presentinvention, such as the various stages of malaria infection.Additionally, the association between various factors can be tested ormonitored even during the interaction process using the method of thesubject invention.

Weak Binding Analytes-Multivalency

The multivalent feature of the polymer-linked ligands of the subjectinvention provide a heightened binding capacity in the case of naturallymultivalent analytes. Multivalency can also be provided for limitedvalency analytes prior to the test procedure to imbue them with thisadvantage of the subject invention. The inventive exploitation ofmultivalency allows a specific but weak interaction to be amplified manyfold.

A structural linker of sufficient length and conformability aids inallowing binding of multiple sites on the analyte even when they areconformationally separated on a curved surface. As a result of thesespecial features, the present invention can detect many ligandspreviously unsuitable for assay evaluation.

The main criteria for effective indication of the presence of analyte isthat the surface of the polymeric assemblies be sufficiently perturbedto produce the requisite spectral change. Binding the analyte to animmobilizing particle will serve this purpose, as it concentrates theanalyte in a small area, and further provides a three-dimensional aspectover a relatively large area to even a small analyte.

A large variety of ligands can be employed in the subject invention,allowing great flexibility in detecting a multivalent test target.Ligand selection can be based on the most advantageous binding andsteric characteristics, rather than compromising these factors toaccommodate the test system. Thus, the most advantageous ligand can beselected based on such factors as hydrophobicity and hydrophilicity,size, position of binding site, and conflicting affinities. Ligandswhich can be employed in the subject invention can includecarbohydrates, peptides, nucleotides, heterocyclic compounds, and otherorganic molecules.

Challenging Analytes

The rigor and outstanding advantages of the inventive assay systemallows the detection and quantitative evaluation of materials which havebeen previously unachievable because of the limitations of the prior artmethods.

The inventive construct and method can assay very small biological orother molecules for which antibodies can not be developed. These targetmaterials can include organic solvents or pollutants present atextremely low levels. There are special opportunities made available bythe advances achieved by the subject inventors for drug screening inboth forensic and clinical applications. Inhibition techniques appliedto the subject invention can allow the testing of materials which are ofa tiny size or have a small number or single valiancy.

While applicants are not bound there by, it is hypothesized by theinventors that the unexpected spectral signal achieved by the presentinvention is due to a physical perturbation of the polymeric assemblieswhich occurs as a result of the binding event. It is the case thatmultivalent materials, such as viruses and cell membrane fragments, canbe very easily detected using the subject inventive method. Thus,multivalent materials generally elicit a particularly strong response inthe subject system. This may be the case because of conformationalchanges introduced into the lipid bi-layer as a result of bindingcausing physical reconfiguration of structure.

If applicants theory holds true, pre-binding of smaller, single valentanalyte materials to a carrier may prove advantageous to increasing theefficacy of the subject invention in those cases. For instance, theanalyte could be bound to a polymer or the surface of a liposome. Thiswould concentrate the binding event on the inventive polymericassemblies surfaces to specific points, increasing the spectralmodification at each point of contact. Additionally, the curved surfaceof the liposome to which the analyte is attached will likely serve totug the peripheral bound analytes away from the bilipid surface andforce analytes centrally located on the liposome into the bilipidsurface. This pre-binding step then can result in increased torsion,perturbation and signal generation on the bilayer surface.

Signal Observation

Various spectral changes to the bi-layer can be used to detect thepresence or absence of the target material. Means of amplifying thespectral signal well known in the art, such as scintillators, can alsobe employed when low levels of analyte are present. Because of theempirical nature of the signal, there are many opportunities forautomating the read out of the present inventive assay system.

In one particular embodiment of the present invention, a blue pink colorshift can be observed simply by visual observation by the testingtechnician. Because of the simplicity of the observation, this functioncan easily be accomplished by an untrained observer such as an at-homeuser. Alternatively, spectral test equipment well known in the art canbe employed to determine a change in spectral qualities beyond thelimits of simple visual observation, including optical density to aparticular illuminating light wavelength.

The subject assemblage can also be optimized in assays by binding themto any one of a number of immobilizing materials and objects. Bonding tosephedex beads, for instance, would allow flow-through and washes to bepossibly during the assay procedures. The inventive assemblies couldeven be embedded in a gel, with the analyte defussing through it,possibly with an electrical gradient.

BRIEF DESCRIPTION OF THE DRAWINGS

The file of this patent contains at least one drawing executed in color.Copies of this patent with color drawing(s) will be provided by thePatent and Trademark Office upon request and payment of the necessaryfee.

FIG. 1 shows (1) a bifunctional molecule and (2) pentacosadiynoic acid.

FIG. 2 is a color photograph showing a suspension of the inventiveliposomes before and after introducing analyte.

FIG. 3 shows wavelength versus absorbance plots for (A) blue liposomesolution and (B) purple liposome solution without virus (solid line) andafter incubation with influenza virus (dashed line).

FIG. 4 shows a plot of the colorimetric response of a purple liposomesolution in response to successive additions of influenza virus.

DETAILED DESCRIPTION OF THE INVENTION

The inventive three-dimensional polymeric assemblage allow for thedirect detection of the presence of a wide range of analytes by changesin color. The results can be read by an untrained observer, and the testcan be conducted in ambient conditions. Very mild testing conditions arepossible, which allows the detection of small biomolecules in a nearnatural state, providing information as to their interactions andavoiding the risk of modification or degradation of the analyte.

The inventive polymer assemblies are composed of a three-dimensionalstructure, such as a liposome or tubule whose surface contains bothorienting and detecting head groups. The detecting head groups arecomposed of a ligand specific to the analyte in question, which is boundto one terminal end of a linear structural linker. This linker, in turn,is bound to the polymeric assemblies by its second terminal end. Thepolymeric assembly surface is also provided with lipid ordering headgroups.

FIG. 1 provides a schematic depiction of one embodiment of the presentinvention. Receptor-binding ligand 1 is shown attached to one terminalend of spacer molecule 3. The second terminal end of spacer molecule 3is then attached to one of several monomers which have been polymerizedinto a chromatic detection element 5. These materials are then agitatedwhile polmyerization occurs, causing the formation of the polymericstructures, such as liposomes and tubules.

Lipid Ordering Groups

The lipids appear to be important in structurally ordering thethree-dimensional polymeric assemblies so that binding of the analyteproduces a detectable color change. Applicants hypothesize that astructuring effect of the ordering groups serves to appropriatelystabilize the physical structure of the three-dimensional polymericassemblies to facilitate color stability and polymerization. In turn,the binding of the analyte to the molecular recognition ligand groupsthen causes sufficient steric perturbation or stress of the structure toresult in a color change. It may be that the stability and relativerigidity engendered by the ordering lipids so unites the bilayersurface, that a steric change in one area triggers a larger effect inthe surface of the assemblies as a whole.

It is not certain which of the many results of binding result in theobserved spectral changes. Most likely the changes are due to stressesinduced by binding which changes the effective conjugation length of thepolymer backbone. The inventive three-dimensional structures are highlycolor sensitive to a number of environmental parameters, such as heat,and these factors may be a component of the observed phenomena as well.However, the applicants are not bound to any of the above hypothesiswhich are simply attempts to explain the demonstrated effective assaymethod of the subject invention.

Previous studies have suggested that color transitions inpolydiacetylenes arise from changes in the effective conjugation lengthof the polydiacetylene backbone and that the electronic structure of thepolymer backbone is strongly coupled to side chain conformation. Theinventors can only speculate at this point that specific virus-liposomeinteractions may serve to alter side chain conformation, reducing theeffective conjugation length of the enzyme backbone. Indeed, theoreticalcalculations suggest that very slight around the C--C bond of thepolymer backbone decrease the π electron delocalization.

Materials for use are as head groups in the present invention include--CH₂ OH, --CH₂ OCONHPh, --CH₂ OCONHEt, --CH₂ CH(Et)OCONHPh, --(CH2)₉OH, --CH₂ OCOPh, --CH₂ OCONHMe, --CH₂ OTs, --CH(OH)Me,

--CH₂ OCOR₂, wherein R₂ is n--C₅ H₁₁, n--C₉ H₁₉. n--C₉ H₁₉, n--C₁₁ H₂₃,n--C₁₃ H₂₇, n--C₁₅ H₃₁, n--C₁₇ H₃₅,Ph, PhO, or o--(HO₂ C)C₆ H₄,

--OSO₂ R₂, wherein R₂ is Ph, p--MeC₆ H₄, p--FC₆ H₄, p--CIC₆ H₄, pBrC₆H₄, p--MeOC₆ H₄, m--CF₃ C₆ H₄, 2-C₁₀ H₇, or Me--

C₂ M, wherein M is K,HNa, or Ba/2.

The preferred materials which can be employed as head groups in thepresent invention are:

--CH₂ OCONHR₂ or --CH₂ CONHR₂ where R₂ is Et, n--Bu, n--C₆ H₁₃, n--C₈H₁₇, n C₁₂ H₂₅, cyclo C₆ H₁₁, Ph, p--MeC₆ H₄, m--MeC₆ H₄, o--CIC₆ H₄,m--CIC₆ H₄, p--CIC₆ H₄, o--MeOC₆ H₄, 3-Thienyl, Me, Et, Ph, l--C₁₀ H₇,Et, Ph, EtOCOCH₂, BuOCOCH₂, Me, Et, i--Pr, n--C₆ H₁₃, EtOCOCH₂,BuOCOCH₂, Ph, 2,4(NO₂)₂ C₆ H₃ OCH₂, or CH₂ CH₂ OH.

The most preferred head groups are taken from --CH₂ COX, where X is OH,MeO or any salt thereof.

Ligand Group

The ligand group of the present invention can be of a wide variety ofmaterials. The main criteria is that the ligand have an affinity for theanalyte of choice. The ligand may be of a broad range, such as when aclass of materials is to be assayed. Appropriate ligands includepeptides, carbohydrates, nucleic acids or any organic molecules whichbind to receptors. For instance, all influenza strains share bindingsites to a host receptor molecule. Thus, this molecule can successfullybe employed to screen for all influenza strains, including those whichhave not yet been characterized.

Ligands can also be used in the present invention when they function ascompetitive binders to the analyte. For instance, a pathogen could beintroduced with a test material which is to be the presence of receptormolecule. In absence of this molecule, the pathogen will bind to thethree-dimensional polymeric structure and produce a color. To the degreethat the pathogen surface is bound to the receptor molecule introducedin the test material, the binding will be diminished. In this way, thepresence of receptor molecule can be detected and quantified.

Receptor-Binding Molecules

The use of sialic acid derivatives in one preferred embodiment describedin the examples below is an example of the use of receptor-bindingmolecules in this capacity. Receptor-binding molecules are materials onthe surface of a host cell to which a pathogen attaches itself as aprelude to the infective event. Selecting these molecules at the ligandgroup in the present invention has many advantages over other receptormolecules.

The recognition site for these molecules tend to be highly geneticallyconserved in the pathogen because of its obvious criticality tosurvival. Therefore, different strains of the same pathogen willgenerally not produce a false negative when such molecules are selectedas the ligand group in the subject invention. Also, receptor moleculestend to be smaller and less complex, and often less hydrophobic, thenantibodies to the same analyte.

An increasing number of receptor molecules are being recognized,identified, isolated, and synthesized for a large number of pathogens.Many have been improved for use in various analytic and treatmentsystems. An example of this trend in research is the sialic acidderivative used in the example below of the subject invention. Examplesof the receptors for a number of pathogens are provided in theapplication as Table 1. All of these, as well as many more, could beexploited by the method of the subject invention.

Lipid Polymerization Groups

Many different polymerizing groups have been incorporated into lipidsand are shown to be effective in monolayer polymerizations. Suchmoieties include: acetylenes, diacetylenes, alkenes, thiophenes, imides,acrylamides, methacrylates, vinylether, malic anhydride, urethanes,allylamines, siloxanes or vinylpyridinium etc. Lipids containing thesegroups can be made into homopolymers or mixed polymers. The preferredgroup for use in this invention is the diacetylene due to its uniqueoptical properties in the polymerized form: polydiacetylene. However,other polymerizing groups could be used when they provide an observablechange in properties upon a binding event.

Forms of the Assemblies

The three-dimensional assemblies of the subject invention can beproduced in any number of forms. One of the most important forms whichcan be produced are liposomes. Several methods for producing the subjectassemblies into that particular form are fully set forth in the Examplesection of this application.

The liposomes of the subject invention can be formed in a number ofdifferent sizes and types. For instance, it is possible to form theliposomes as simple bi-layer structures. Additionally, they can bemulti-layered, in an onion type structure. Their size can also bevaried.

Numerous other shapes can also be produced. Double chains (Kuo et al,Macromolecule, p 3225, Vol. 23 1990), lamellae (Rhodes, et al Langmuir,p 267 Vol.10, 1994), hollow tubules and braids (Frankel et al, Journalof the American Chemistry Society, Vol. 116, 1994), among other shapescan be formed. When these assemblies are immobilized, they cancollectively form even larger constructs.

One example of a successful protocol for producing the liposomeembodiment of the subject invention is as follows:

mixing of the appropriate amounts of the chloroform solutions of thelipids (1-15 mM) in a small vial

evaporation of the chloroform with a stream of nitrogen

addition of the appropriate amount of de-ionized water (total lipidconcentration 1-2 mM)

heating of the solution above the phase transition of the lipids (about80-90° C.)

sonication of the solution for 15 minutes (probe sonicator, Fisher sonicdismembrator model 300, 50% maximum output, microtip)

filtration of the warm opaque solution through a 0.8 μm nylon filter(Gelman) to remove small titanium particles from the solution

cooling of the solution for at least one hour up to one day in thefridge (4° C.)

removal of the oxygen in the solution by bubbling nitrogen through thesample for 5-10 minutes prior to polymerization

polymerization of the stirred liposome solution in a 1 cm quartz cuvettewith a small 254 nm UV-lamp (pen-ray, energy: 1600 μw/cm²) in a distanceof 3 cm in a small chamber which is purged with nitrogen 20 minutesprior to and during the polymerization to replace all oxygen and to coolthe sample; polymerization times vary between 5 and 30 minutes dependingon the desired properties (color, polymerization degree) of theliposomes.

EXAMPLE 1

As shown in FIG. 1, the bifunctional molecule 1 use in one embodiment ofthe subject invention incorporates both the sialic acid ligand for viralbinding and the diacetylenic functionality in the hydrocarbon chain forpolymerization. The carbon-glycoside in this compound was designed toprevent hydrolysis by viral neuraminidase. This compound was mixed with10-12-pentacosadiynoic acid 2 and hydrated to form liposomes. Althoughmost natural lipids that form liposomes consist of two alkyl chains,synthetic liposome-forming lipids with only one alkyl chain also exist.See, for example: Hupfer et al Phys. Lipids, pp 355-374 Vol. 33, andBader, Chem., Int. Ed. Engl., pp 91-92 Vol. 20, 1981. Previous studiesindicated that optimum viral binding occurs for mixtures of 1-10%compound 1 in the liposome Spevak et al, J. Am. Chem. Soc., 161, 115 &p. 1146, 1993. Therefore, 5% and 10% sialic acid lipid were used in thiscalorimetric detection study.

Liposomes were prepared using a probe sonication method, [Liposomes: APractical Approach; New, Ed.; Oxford University Press; Oxford, pp33-104, 1990,] and subsequently polymerized by irradiation at 254 nmusing an ultraviolet pencil lamp. FIG. 3 shows calorimetric detection ofinfluenza virus by polymerized diacetylene liposomes (5% sialic acidlipid 1), including the visible absorption spectra of (A) blue liposomesolution (8 min UV) and (B) purple liposome solution (24 min UV) withoutvirus (solid line) and after incubation with 60 HAUs of influenza virus(dashed line). The concentration of the liposome solutions in PBS bufferwas 0.13 mM, and the incubation time with the virus was 1 h.

Irradiation of a liposome solution (1 mM in deionized water) for about5-10 min results in the formation of deeply blue colored liposomes(Table 3A, solid line). If the polymerization time is longer (between 10and 30 min), a purple color is observed (Table 3B, solid line). Wheninfluenza virus is added to the liposomes in PBS buffer, the solutionimmediately changes to a pink or orange color, depending on whether theinitial preparation was blue or purple, respectively (Table 3A and B,dashed curves). These color changes are readily visible with the nakedeye and can be quantified by visible absorption spectroscopy.

The colorimetric response (CR) is quantified by measuring the percentchange in the absorption at 626 nm (which imparts the blue color to thematerial) relative to the total absorption maxima. In order to quantifythe response of a liposome solution to a given amount of virus, thevisible absorption spectrum of the liposome solution without the viruswas analyzed as

    B.sub.o =I.sub.626 /(I.sub.536 +I.sub.626)

where B_(o) is defined as the intensity of absorption at 626 nm dividedby the sum of the absorption intensities at 536 and 626 nm. The liposomesolution which was exposed to influenza virus was analyzed in the sameway as

    B.sub.v =I.sub.626 /(I.sub.536 +I.sub.626)

where B_(v) represents the new ratio of absorbance intensities afterincubation with the virus; The calorimetric response (CR) of a liposomesolution is defined as the percentage change in B upon exposure to virus

    CR=[(B.sub.o -B.sub.v)/B.sub.o ]×100%

To be consistent with the inventors' earlier work, the absorption maximaat 626 and 536 nm was arbitrarily chosen to calculate the percentageblue absorption for the liposomes solutions. Use of the secondabsorption maximum at 480 nm for the calculations does not change therelative trend of the results shown.

As shown in FIG. 3, incubation of the blue liposomes (8 min UV) with 60hemagglutinating units (HAUs) of virus leads to a CR of 47%; incubationof the purple liposomes (24 min UV) with the same amount of virus givesa CR of 87%. A hemagglutinating unit (HAU) is a measure of the highestdilution of the virus solution that still completely agglutinates a 1%solution of red blood cells. The inventors speculate that the enhancedsensitivity of the purple liposomes may be due to an increased polymercontent, as suggested by their higher optical density (data not shown).

No color change could be detected if pure PBS buffer or a solution ofBSA in PBS buffer (1 mg/mL) was added to the liposome solution (CR≦5%within 2 h). In order to directly address the effects of nonspecificadsorption, liposomes were prepared without sialic acid lipid 1 inFIG. 1. Similarly, these liposomes did not change color after exposureto virus.

EXAMPLE 2

The specific nature of the interaction between the influenza virus andthe sialic acid liposomes was confirmed by a competitive inhibitionexperiment. Incubation of a liposome solution (10% sialic acid lipid 1)with 54 HAUs of influenza virus yields a CR of 31% for blue and 70% forpurple liposomes. Performing the same experiment with a slight excess ofa-O-methyl-neuramatic acid, a known inhibitor for influenza virushemag-glutination, results in no color change.

Kinetic experiments show that the color change induced by the additionof an aliquot of virus reaches a plateau after 30 min. although thechange becomes apparent within 5 min. For a given polymerization time,the CR depends on the amount of added virus, as shown in FIG. 4. FIG. 4is the plot of the calorimetric response of a purple liposome solution(5% sialic acid lipid 1, 24 min UV) versus successive additions ofinfluenza virus. The liposomes were incubated for 30 min following eachaddition of virus, and the visible absorption spectrum was recorded. TheCR for each virus concentration was obtained in three independentexperiments.

Given that the color change of the liposomes in buffer without virus isless than 4% within 2 h, a CR of 5% or more in a few minutes isconsidered significant. Therefore, the amount of virus required toproduce a CR just above this value defines the detection limit of themethod in this particular embodiment. The titration curve in FIG. 4shows that as little as 11 HAUs can be detected. This corresponds toapproximately 11×107 virus particles by electron microscopy count.

The subject inventors have demonstrated that polymerized structuresincluding liposomes are biomolecular materials that provide a molecularrecognition function (sialic acid) and a detection element(polydiacetylene backbone), all within a single supramolecular assembly.The binding event in transduced to a visible color change, readily seenwith the naked eye and quantified by absorption spectroscopy.Specificity of the color change was demonstrated by competitiveinhibition studies. In addition, nonspecific adsorption, if it occurs,does not appear to affect the color of the liposome solutions.

EXAMPLE 3

Immobilizing Liposomes to Substrates

Attachment to membranes of poly(ether urethanes) or polyacrylonitrile.These membranes are porous, hydrophilic and can be used for affinityseparations or immunodiagnosis. The liposomes can be coupled to thesemembranes by first attaching to the membrane an activating group such asimidizolyl-carbonyl, succinimido, FMP or isocyanate which adds rapidlyto nucleophiles in the liposomes such as --NH2, --SH, --OH. Thus, anyliposome preparation which contains these functionalities can bedirectly attached to the membrane. This procedure is analogous to thecoupling of proteins to membranes the latter of which can be found inthe literature. (C. H. Bamford, K. G. Al-I,amee, M. D. Purbrick, T. J.Wear, J. Chromatography, 1992, 606, 19 or C. H. Bamford, K. G. Allamee,Clinical Materials, 1992, 10, 243. In principle, any strategy previouslydeveloped to immobilize proteins can be used to immobilize liposomes.

Liposomes which have an --SH functionality can also be immobilizeddirectly to gold surfaces, particles, or electrodes via the thiol-goldbond. In this case, a solution of the liposomes containing the --SHgroup are incubated with the clean gold surface in water for 12-24 hourswith stirring at room temperature.

Liposomes can be immobilized to silicon chips or silica gel (silicondioxide) using the following procedure. The gel or wafers are acidcleaned in 1:1 HCl,-methanol, rinsed in water, and placed inconcentrated sulfuric acid. After a thorough water rinse, the waferchips or gel is boiled in doubly distilled deionized water, allowed tocool and dry and then silanized under inert atmosphere in a 2% solutionof 3-mercaptopropyl trimethoxysilane prepared in dry toluene. Next, thechips or gels are placed in a 2 mM solution of either GMBS(N-succinimidyl 4-maleimidobutyrate) or EMCS (N-succinimidyl6-maleimidocaproate) prepared in 0.1 M phosphate buffer (the crosslinker is first dissolved in a minimal amount of dimethylformamide).After rinsing with phosphate buffer, the chips are placed in a 0.05mg/ml solution of the liposomes prepared in pH 8.0 phosphate buffer.Finally, the chips or gels are thoroughly rinsed with, and then storedin, the buffer solution prior to their use. The liposomes should have an--NH2 functionality for the cross-linking with GMBS or EMCS to work.This procedure is a modification of a previously developed procedurewhich was used to immobilize enzymes to silicon chips or gels. It hasbeen modified for the liposome immobilization. (from K. M. Rusin, T. L.Fare, I. Z. Stemple, Biosensors and Bioelectronics, 1992, 7, 367).

--NII2 functionalized liposomes can also be immobilized onto surfaces byuse of standard gluteraldehyde coupling reactions such as often usedwith the immobilization of proteins.

EXAMPLE 4

Detection and Screening

The liposomes can be used to replace standard radiolabel assays forligand-receptor screening. For example, if the ligand is an analog ofdopamine (e.g. the compound "spiperone"), the ligand can be incorporatedinto polymerized liposomes (polymerized assemblies). If the membranereceptor for dopamine, such as the dopamine D-2 receptor is added to thespiperone-modified liposomes, a color change from blue to pink isobserved. This can be monitored spectroscopically in a manner similar tothe detection of viruses and bacteria. The effect can be inhibited bythe addition compounds which bind as strongly or stronger than dopamineor spiperone. By using a 96-well plate format, 96 compounds which areanalogs of dopamine can be screened as potential new drugs. This highthroughput screening does not require the use of expensive radiolabelledcompounds and does not have the associated health and safety problems.

Procedure: Dilute 20-50 uL of liposome solution which contain from0.5%-20 % of the spiperone ligand in 100-200 uL, of an appropriatelybuffered medium. The solution will have a blue or purple color. Thevisible absorption spectrum of the sample can be recorded at this point.For detection study: add the dopamine D2 membrane receptor preparationin successive aliquots starting at 10-50 uL until 100-200 uL. The colorchange can be observed by eye or by recording of the visible absorptionspectrum. For drug screening studies: Add the dopamine D2 membranereceptor preparation mixed with the new ligand or new drug compound.Allow for binding to occur by incubating at room temperature or at 37°C. for 5-60 minutes. Add the inhibited membrane receptor preparation tothe diluted liposome solution. If the solution turns pink, the newligand or drug was ineffective. If the solution remains blue, the newligand or drug was an effective binder to the receptor.

EXAMPLE 5

Detection of Radioactive Metals.

The monomeric diynes can be polymerized by exposure to gammairradiation. By incorporating a ligand which is a metal chelator, themonomeric form of the liposomes are exposed to a solution of radioactivemetals. Upon binding of the metal to the chelator ligand, the emittedgamma irradiation serves to polymerize the liposomes. The solutionchanges from a whitish opaque solution (unpolymerized liposomes) to adeep blue or deep red solution of the polymers. The liposomes serve twopurposes: 1) to detect the presence of the radioactive metals, and 2) toclean the solution of the radioactive metals. Step 2 is accomplished bysimply filtering or centrifuging the metal-bound liposomes. Thisprocedure can be referred to as "seen and cleaned" since the liposomesboth detect and purify the radioactive metals from the surroundingenvironment.

Procedure: Prepare liposomes as described up until the point of UVirradiation. The monomeric liposomes will have an opaque, whitishappearance. For detection: Dilute 10-100 uL of liposomes in 50 200 uL ofwater or appropriate buffer. The liposomes will contain 0.5%-20% of thechelator ligand. This can be done in a 96-well plaet format. Add theenvironmental sample to be tested, 50-100 uL. Observe the formation of ablue to red color indicating the presence of gamma irradiation, andhence the radioactive metal. For large scale cleanup purposes, theliposomes can be immobilized onto large filtration units near the effluxof wastewater treatment areas, for example, as found at Superfund cleanup sites or at other DOE facilities. The treated water passes over thefiltration units. Any remaining radioactive metals in the water will bedetected by a blue or red color on the filtration unit. At the sametime, these metals will be cleared from the treated water such that thewater can be returned to the environment or retested.

EXAMPLE 6

Glucose Sensor

The liposomes are sensitive to pH. At high pH the liposomes are in thered state and at low pH the liposomes are in the blue state. The effectcan be made reversible. The liposomes can be used to detect smallmolecule analytes which in the presence of an appropriate enzyme orother metabolic cellular process changes the pH of its surroundingmedia. For example, in the detection of glucose. The liposomes are addedto a media of sufficiently high pH to put them in the red state. 10-50uL of liposomes can be diluted with 50-200 uL of the appropriate media.The test sample is added, 10-100 uL. This can be done in a 96-well plateformat. To the test sample is added 10-50 uL of glucose oxidase. Ifglucose is present, the glucose oxidase will convert glucose toglucaraonic acid. This conversion will lower the pH of the solution,producing the blue state of the liposomes. This red to blue color changesignifies the presence of glucose in the sample. The test can be donevisually or quantitatively by measuring the visible absorption spectrum.

                  TABLE 1                                                         ______________________________________                                        Pathogen       Receptor Molecule                                              ______________________________________                                        HIV            D4.sup.14 ; Vasoactive Intestinal Peptide.sup.7,                              Peptide T.sup.8, Sialic Acid.sup.12                            Vaccinia       Epidermal Growth Factor.sup.1                                  Rabies         Acetylcholine receptor.sup.2                                   Epstein Barr   Complement Receptor.sup.3,4                                    Rheo           Beta-adrenergic receptor.sup.3                                 Rhinovirus     ICAM-1.sup.6,10,11 ; N-CAM, myelin-associated                                 glyeoprotein MAb.sup.13                                        Polio viruses  Polio viruse receptor.sup.9                                    Influenza      Sialic Acid.sup.15                                             Cytomegalovirus                                                                              Glycoprotein (not Sialic Acid).sup.16,17,18                    Coronaviruses  9-OAC Sialic Acid & Sialic Acid                                Encephalomyelitis                                                                            9-OAC Sialic Acid                                              Rubella Virus                                                                 .sup.19                                                                       Measles Virus  Glycoprotein (not Sialic Acid).sup.20,21,22,23                 Herpes         Oligosasaccharioes Glycoprotein.sup.24,25,26                   Chlamydia      Sialic Acid.sup.27,28,29,30                                    Rhinovirus     Glycosylated Proteins.sup.31,32                                Rotavirus      9-OAC Sialic Acid                                              Polyomavirus   Sialic Acid                                                    Reovirus       Sialic Acid                                                    Streptococcus Suis                                                                           Sialic Acid α 2 → 3 Poy-N-Acetyl-                                lactosamine                                                    Salmonella Typhimurium                                                                       Sialic Acid                                                    Paramyxovirus                                                                 Sendi Virus    Sialic Acid                                                    Mumps          Sialic Acid                                                    Newcastle Disease Virus                                                                      Sialic Acid                                                    Myxoviruses    Sialic Acid                                                    Escherichia Coli                                                                             Oligomannose, Galactose α 1 → 4                                  Galactose, Sialic Acid α 2 → 3 Galactose          Encephalomyocarditis Virus                                                                   Sialic Acid                                                    Cholera Toxin  G.sub.m9 (A Gangliosial of Sialic Acid,                                       Galactose, Glucose, N-Acetyl Galactos)                         Meningitis     Sialic Acid                                                    ______________________________________                                         .sup.1. Nature, 318: 663 (1985)                                               .sup.2. Science, 215: 182 (1982)                                              .sup.3. Proc. Natl. Acad. Sci. USA, 81: 4510 (1984)                           .sup.4. J. of Biol. Chem., 265: 12293 (1990)                                  .sup.5. Proc. Natl. Acad. Sci. USA, 82: 1494 (1985)                           .sup.6. Nature, 344: 70 (1990)                                                .sup.7. J. of Neuroscience Research, 18: 102-107 (1987)                       .sup.8. FEBS Letters, 211: 17-22 (1987)                                       .sup.9. Cell, 56: 855-865 (1989)                                              .sup.10. Cell, 56: 839-842 (1989)                                             .sup.11. Cell, 56: 849-853 (1989)                                             .sup.12. Nature, 333: 426-431 (1988)                                          .sup.13. Proc. Natl. Acad. Science, USA, 85: 7743-47 (1988)                   .sup.14. Nature, 312: 763-770 (1985)                                          .sup.15. Cell, 56: 725-728 (1989)                                             .sup.16. J. Virol, 63: 3991 (1989)                                            .sup.17. Inas, 86: 10100 (1989)                                               .sup.18. Virol, 176: 337 (1990)                                               .sup.19. Med. Microbio. Imm., 179: 105 (1990)                                 .sup.20. Infect. Imm., 24: 65 (1979)                                          .sup.21. Proc. Soc. Exp. Bio Med, 162: 299 (1979)                             .sup.22. Virol, 172: 386 (1989)                                               .sup.23. J. Clin. Inv, 86: 2569 (1990)                                        .sup.24. J. Virol, 64: 2569 (1990)                                            .sup.25. Science, 248: 1410 (1990)                                            .sup.26. Febs Lett., 277: 253 (1990)                                          .sup.27. Infec. Imm., 57: 2378 (1989)                                         .sup.28. Microb. Lett., 57: 65 (1989)                                         .sup.29. Infect. Imm., 40: 1060 (1990)                                        .sup.30. Infect. Imm., 25: 940 (1983)                                         .sup.31. Med. Virol, 8: 213 (1989)                                            .sup.32. J. Virol, 64: 2582 (1990)                                       

We claim:
 1. A composition comprising liposomes, wherein said liposomescomprise:a) a plurality of polymerized diacetylene lipid monomerswherein said monomers contain head groups selected from the groupconsisting of carboxylic acid, hydroxyl groups, amine groups, amino acidderivatives, and hydrophobic groups; and b) one or more ligands selectedfrom the group consisting of proteins, antibodies, peptides,carbohydrates, nucleic acids, and combinations thereof wherein saidligands are attached to said liposomes;wherein said liposomes changecolor in the presence of one or more analytes, and wherein saidliposomes are made by a method comprising the steps of: 1) combiningsaid lipid monomers and said one or more ligands in an organic solvent;2) evaporating said organic solvent to produce a concentratedlipid-ligand mixture; 3) adding an aqueous solution to said concentratedlipid-ligand mixture to produce an aqueous lipid-ligand mixture; 4)agitating said aqueous lipid-ligand to produce an agitated lipid-ligandmixture; 5) cooling said agitated lipid-ligand mixture to at least about4° C. to produce liposomes; and 6) polymerizing said liposomes.
 2. Thecomposition of claim 1, wherein said liposomes comprise braided,lamellar, helical, tubular, and fiber-like shapes, and combinationsthereof.
 3. The composition of claim 1, wherein said analytes areselected from the group consisting of pathogens, drugs, radioactivemetals, glucose and lectins.
 4. The composition of claim 3, wherein saidpathogens are selected from the group consisting of viruses, bacteria,parasites, and fungi.
 5. The composition of claim 4, wherein saidviruses are selected from the group consisting of influenza, rubella,varicella-zoster, hepatitis A, hepatitis B, herpes simplex, polio, smallpox, human immunodeficiency virus, vaccinia, rabies, Epstein Barr,reoviruses, and rhinoviruses.
 6. The compositions of claim 4, whereinsaid bacteria are selected from the group consisting of E coli,Mycobacterium tuberculosis, Salmonella, and Streptococcus.
 7. Thecomposition of claim 4, wherein said parasites and other pathogens areselected from the group consisting of Plasmodium, Trypanosoma,Toxoplasma gondii, and Onchocerca.
 8. The composition of claim 1,further comprising a support wherein said liposomes are bound to saidsupport.
 9. The composition of claim 8, wherein said support is selectedfrom the group consisting of sephadex, silica gel, sepharose,polyacrylonitriles, filters, gold, silicon chips, and silica gel.
 10. Atest kit comprising a container and said composition of claim
 1. 11. Thetest kit of claim 10, wherein said composition is contained within atleast one well.
 12. The composition of claim 1, wherein said polymerizedlipid monomers comprise polydiacetylene lipid monomers.